Meanwhile, KEYNOTE-81124 had reported the combination of pembrolizumab, trastuzumab and chemotherapy, which provided a substantial, statistically significant improvement in ORR compared with placebo, trastuzumab, and chemotherapy for HER2-positive advanced gastric cancer patients. This evidence concerns the gene ERBB2 and gastric cancer.